Damora Therapeutics, Inc. (GLTO) Form 8-K — May 4, 2026
Damora Therapeutics announced that Chief Financial Officer Lori Firmani will cease her duties effective May 1, 2026. Subject to the execution of a separation agreement, Ms. Firmani is entitled to severance benefits including a lump sum payment of salary and bonus, a $6,000 health savings account contribution, and full acceleration of her equity awards. Brian Burkavage, the company's current Senior Vice President of Finance, has been appointed to serve as principal financial officer and principal accounting officer effective immediately.
Key figures
- Severance Hsa Contribution
- 6000
Price after filing
Close on the filing date to close N calendar days later (from $25.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.